Oculus sales rise 33 percent

Petaluma medical device startup Oculus Innovative Sciences posted $1.6 million in revenue for the third quarter, up 33 percent from the same period a year ago, the company said Thursday.

Oculus makes Microcyn liquid and gel products for cleaning and treating wounds.

The company lost $1.3 million or 5 cents a share last quarter, compared to $3.3 million or 21 cents a share a year ago.

Oculus is growing sales in the U.S., where it has FDA approval to market Microcyn as a medical device, said CEO Hoji Alimi. The company is seeking FDA approval for new versions of Microcyn for oral, dermatology, allergy and other applications, he said.

Microcyn has approval for wider applications in several countries outside the United States. Oculus products are marketed in the U.S., Europe, China, India and Mexico.

Oculus has 74 employees, including 27 at its Petaluma headquarters.